(S)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-4-tert-butoxy-2-methyl-4-oxobutanoic acid | 1231709-26-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 英文名称: (S)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-4-tert-butoxy-2-methyl-4-oxobutanoic acid
• 英文别名: (R)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-4-(tert-butoxy)-2-methyl-4-oxobutanoic acid；(2R)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-2-methyl-4-[(2-methylpropan-2-yl)oxy]-4-oxobutanoic acid
• CAS: 1231709-26-4
• 化学式: C₂₄H₂₇NO₆
• 分子量: 425.481
• InChiKey: STBMKQNEFSJOCS-XMMPIXPASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  31
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  102
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  9-芴甲基-N-琥珀酰亚胺基碳酸酯 、 O⁴-(tert-butyl) hydrogen (R)-2-methylaspartate 在 sodium carbonate 作用下， 以 1,4-二氧六环 、 水 为溶剂， 以1.100 g的产率得到(S)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-4-tert-butoxy-2-methyl-4-oxobutanoic acid
  参考文献：
  名称：

  具有羧基烷基侧链的手性α-甲基化α-氨基酸的合成和利用，用于设计不含磷酸酪氨酸的新型Grb2-SH2肽抑制剂。

  摘要：

  生长因子受体结合蛋白2（Grb2）是包含SH2域的对接模块，代表抗癌治疗干预的有吸引力的目标。为了提高Grb2-SH2抑制剂的效力和生物利用度，设计了手性α-甲基-α-羧基烷基氨基酸[（α-Me）Aa]，以涵盖1-氨基环己烷羧酸（Ac6c ）和Y + 1处的α-氨基己二酸（Adi）。通过优化的恶唑烷酮方法可方便地合成带有各种链长羧基烷基侧链的对映体纯1（或D）-（α-Me）Aa。（S）-（α-Me）Aa掺入具有X（-2）-Leu-（3' -取代的Tyr）（0）-X（+1）-Asn确实提高了抑制活性，提供了强力的（R）-亚砜桥连的环状和Grb2-SH2域的五肽抑制剂的开链系列（IC 50 = 1.1-5.8 microM）。更重要的是，由于肽性质的降低和pTyr或Pdyr的缺失，这些（α-Me）Aa结合的肽抑制剂在抑制具有低微摩尔IC 50值的erbB2依赖性MDA-MB-453肿瘤细胞系生长方面表现出出色的活性。

  DOI：

  10.1021/jm800487r

文献信息

• SYNTHETIC APOLIPOPROTEINS, AND RELATED COMPOSITIONS METHODS AND SYSTEMS FOR NANOLIPOPROTEIN PARTICLES FORMATION
  申请人：LAWRENCE LIVERMORE NATIONAL SECURITY, LLC

  公开号：US20180186860A1

  公开（公告）日：2018-07-05

  Synthetic apolipoproteins based on native/naturally occurring homolog proteins can be prepared using solid-phase peptide synthesis approaches combined with native chemical ligation methods to create analogs of full length apolipoproteins. The chemical synthesis is expected to allow introduction of non-natural amino acids, e.g., α,α′-dialkyl amino acids, with a periodicity that encourages both helix formation and amphipathicity. Such apolipoprotein analogs are expected to encourage, in some embodiments, facile and more complete NLP formation, enabling consideration of full spectrum of nanoparticle-based biotechnology applications ranging from therapeutic sequestration and delivery to energy/biofuel production to biopolymer production.
• [EN] SYNTHETIC APOLIPOPROTEINS, AND RELATED COMPOSITIONS METHODS AND SYSTEMS FOR NANOLIPOPROTEIN PARTICLES FORMATION<br/>[FR] APOLIPOPROTÉINES SYNTHÉTIQUE, ET COMPOSITIONS, PROCÉDÉS ET SYSTÈMES ASSOCIÉS POUR LA FORMATION DE PARTICULES DE NANOLIPOPROTÉINE
  申请人：L LIVERMORE NAT SECURITY LLC

  公开号：WO2017044899A1

  公开（公告）日：2017-03-16

  Synthetic apolipoproteins based on native/naturally occurring homolog proteins can be prepared using solid-phase peptide synthesis approaches combined with native chemical ligation methods to create analogs of full length apolipoproteins. The chemical synthesis is expected to allow introduction of non-natural amino acids, e.g., α,α'-dialkyl amino acids, with a periodicity that encourages both helix formation and amphipathicity. Such apolipoprotein analogs are expected to encourage, in some embodiments, facile and more complete NLP formation, enabling consideration of full spectrum of nanoparticle-based biotechnology applications ranging from therapeutic sequestration and delivery to energy/biofuel production to biopolymer production.
• Synthesis and Utilization of Chiral α-Methylated α-Amino Acids with a Carboxyalkyl Side Chain in the Design of Novel Grb2-SH2 Peptide Inhibitors Free of Phosphotyrosine
  作者：Ya-Qiu Long、Ting Xue、Yan-Li Song、Zu-Long Liu、Shao-Xu Huang、Qiang Yu

  DOI：10.1021/jm800487r

  日期：2008.10.23

  alpha-aminoadipic acid (Adi) in position Y + 1. The enantiopure l(or D)-(alpha-Me)Aa bearing various chain length carboxylalkyl side chain was conveniently synthesized by an optimized oxazolidinone methodology. The incorporation of (S)-(alpha-Me)Aa into the non-pTyr-containing peptide framework with a 5-amino acid sequence binding motif of X (-2)-Leu-(3'-substituted-Tyr) (0)-X (+1)-Asn really improved the

  生长因子受体结合蛋白2（Grb2）是包含SH2域的对接模块，代表抗癌治疗干预的有吸引力的目标。为了提高Grb2-SH2抑制剂的效力和生物利用度，设计了手性α-甲基-α-羧基烷基氨基酸[（α-Me）Aa]，以涵盖1-氨基环己烷羧酸（Ac6c ）和Y + 1处的α-氨基己二酸（Adi）。通过优化的恶唑烷酮方法可方便地合成带有各种链长羧基烷基侧链的对映体纯1（或D）-（α-Me）Aa。（S）-（α-Me）Aa掺入具有X（-2）-Leu-（3' -取代的Tyr）（0）-X（+1）-Asn确实提高了抑制活性，提供了强力的（R）-亚砜桥连的环状和Grb2-SH2域的五肽抑制剂的开链系列（IC 50 = 1.1-5.8 microM）。更重要的是，由于肽性质的降低和pTyr或Pdyr的缺失，这些（α-Me）Aa结合的肽抑制剂在抑制具有低微摩尔IC 50值的erbB2依赖性MDA-MB-453肿瘤细胞系生长方面表现出出色的活性。